{"filing":{"accession_number":"0001193125-26-356877","cik":"0001703647","ticker":"KRRO","company_name":"Korro Bio, Inc.","form":"8-K","filing_date":"2026-08-19","report_date":"2026-08-19","primary_document":"krro-20260819.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526356877/krro-20260819.htm"},"events":[{"id":28490,"run_id":26065,"accession_number":"0001193125-26-356877","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Korro Bio announced submission to the Australian Alfred Health Human Ethics Committee to initiate a Phase 1/2 clinical trial for KRRO-121, a GalNAc-conjugated RNA editing oligonucleotide for hyperammonemia treatment. This is a material operational and clinical development milestone for a biopharmaceutical company—the initiation of first-in-human trials represents a significant advancement in the drug development pipeline that would affect a reasonable investor's assessment of the company's progress and prospects, though it does not fit the specific categories of earnings, M\u0026A, impairment, or other defined event types.","company_name":"Korro Bio, Inc.","ticker":"KRRO","filing_date":"2026-08-19","form":"8-K","submitted_at":null,"items":[{"id":30449,"accession_number":"0001193125-26-356877","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Korro Bio announced submission to the Australian Alfred Health Human Ethics Committee to initiate a Phase 1/2 clinical trial for KRRO-121, a GalNAc-conjugated RNA editing oligonucleotide for hyperammonemia treatment. This is a material operational and clinical development milestone for a biopharmaceutical company—the initiation of first-in-human trials represents a significant advancement in the drug development pipeline that would affect a reasonable investor's assessment of the company's progress and prospects, though it does not fit the specific categories of earnings, M\u0026A, impairment, or other defined event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T20:06:48.419629+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30449,"accession_number":"0001193125-26-356877","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Korro Bio announced submission to the Australian Alfred Health Human Ethics Committee to initiate a Phase 1/2 clinical trial for KRRO-121, a GalNAc-conjugated RNA editing oligonucleotide for hyperammonemia treatment. This is a material operational and clinical development milestone for a biopharmaceutical company—the initiation of first-in-human trials represents a significant advancement in the drug development pipeline that would affect a reasonable investor's assessment of the company's progress and prospects, though it does not fit the specific categories of earnings, M\u0026A, impairment, or other defined event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T20:06:48.419629+00:00","company_name":"Korro Bio, Inc.","ticker":"KRRO","filing_date":"2026-08-19"}]}